Best Practice & Research Clinical Rheumatology
Volume 22, Issue 2 , Pages 299-310 , April 2008

Translating basic research into clinical rheumatology

  • D. van der Woude, MD (Research Fellow)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +31 71 5263265; Fax: +31 71 5266752.
    • ,
  • T.W.J. Huizinga, MD, PhD (Professor, Head of Department)

References 

  1. Tunn EJ, Bacon PA. Differentiating persistent from self-limiting symmetrical synovitis in an early arthritis clinic. British Journal of Rheumatology. 1993;32:97–103
  2. Prevoo ML, van Gestel AM, van T Hof M, et al. Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score. British Journal of Rheumatology. 1996;35:1101–1105
  3. Maini RN, Feldmann M. Immunopathogenesis of rheumatoid arthritis. In:  Isenberg DA editors. Oxford Textbook of Rheumatology. 3rd ed.. Oxford: Oxford University Press; 2004;p. 677–697
  4. Kong YY, Feige U, Sarosi I, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature. 1999;402:304–309
  5. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature. 2003;423:356–361
  6. Liu MF, Kohsaka H, Sakurai H, et al. The presence of co-stimulatory molecules CD86 and CD28 in rheumatoid arthritis synovium. Arthritis and Rheumatism. 1996;39:110–114
  7. Isler P, Vey E, Zhang JH, et al. Cell surface glycoproteins expressed on activated human T cells induce production of interleukin-1 beta by monocytic cells: a possible role of CD69. European Cytokine Network. 1993;4:15–23
  8. Schett G. Cells of the synovium in rheumatoid arthritis. Osteoclasts. Arthritis Research & Therapy. 2007;9:203
  9. Panayi GS. B cells: a fundamental role in the pathogenesis of rheumatoid arthritis?. Rheumatology (Oxford). 2005;44(Suppl. 2):ii3–ii7
  10. Jasin HE, Taurog JD. Mechanisms of disruption of the articular cartilage surface in inflammation. Neutrophil elastase increases availability of collagen type II epitopes for binding with antibody on the surface of articular cartilage. Journal of Clinical Investigation. 1991;87:1531–1536
  11. Mathsson L, Lampa J, Mullazehi M, et al. Immune complexes from rheumatoid arthritis synovial fluid induce FcgammaRIIa dependent and rheumatoid factor correlated production of tumour necrosis factor-alpha by peripheral blood mononuclear cells. Arthritis Research & Therapy. 2006;8:R64
  12. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. The New England Journal of Medicine. 2001;344:907–916
  13. Shingu M, Nagai Y, Isayama T, et al. The effects of cytokines on metalloproteinase inhibitors (TIMP) and collagenase production by human chondrocytes and TIMP production by synovial cells and endothelial cells. Clinical and Experimental Immunology. 1993;94:145–149
  14. Diarra D, Stolina M, Polzer K, et al. Dickkopf-1 is a master regulator of joint remodeling. Nature Medicine. 2007;13:156–163
  15. van Roon JA, van Roy JL, Duits A, et al. Proinflammatory cytokine production and cartilage damage due to rheumatoid synovial T helper-1 activation is inhibited by interleukin-4. Annals of the Rheumatic Diseases. 1995;54:836–840
  16. Radstake TR, Roelofs MF, Jenniskens YM, et al. Expression of toll-like receptors 2 and 4 in rheumatoid synovial tissue and regulation by proinflammatory cytokines interleukin-12 and interleukin-18 via interferon-gamma. Arthritis and Rheumatism. 2004;50:3856–3865
  17. van der Helm-van Mil AH, Verpoort KN, Breedveld FC, et al. The HLA-DRB1 shared epitope alleles are primarily a risk factor for anticyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis. Arthritis and Rheumatism. 2006;54:1117–1121
  18. Kallberg H, Padyukov L, Plenge RM, et al. Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis. American Journal of Human Genetics. 2007;80:867–875
  19. Nielen MM, van Schaardenburg D, Reesink HW, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis and Rheumatism. 2004;50:380–386
  20. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annual Review of Immunology. 2005;23:515–548
  21. Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. The New England Journal of Medicine. 2003;349:1907–1915
  22. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. The New England Journal of Medicine. 2005;353:1114–1123
  23. Todd DJ, Costenbader KH, Weinblatt ME. Abatacept in the treatment of rheumatoid arthritis. International Journal of Clinical Practice. 2007;61:494–500
  24. Janeway CA, Walport M, Travers P, Shlomchik MJ. Immunobiology: the immune system in health and disease. 6th ed.. New York: Garland Science Publishing; 2005;
  25. Wiederrecht G, Lam E, Hung S, et al. The mechanism of action of FK-506 and cyclosporin A. Annals of the New York Academy of Sciences. 1993;696:9–19
  26. Kitahara K, Kawai S. Cyclosporine and tacrolimus for the treatment of rheumatoid arthritis. Current Opinion in Rheumatology. 2007;19:238–245
  27. Grillo-Lopez AJ, Hedrick E, Rashford M, et al. Rituximab: ongoing and future clinical development. Seminars in Oncology. 2002;29:105–112
  28. Edwards JC, Cambridge G, Leandro MJ. B cell depletion therapy in rheumatic disease. Best Practice & Research. Clinical Rheumatology. 2006;20:915–928
  29. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. The New England Journal of Medicine. 2004;350:2572–2581
  30. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to antitumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis and Rheumatism. 2006;54:2793–2806
  31. Leandro MJ, Cambridge G, Ehrenstein MR, et al. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis and Rheumatism. 2006;54:613–620
  32. Schneider M. Exploring new territory: considering the future. Lupus. 2007;16:221–226
  33. Huizinga TW, Boling E, Valente R, et al. Genetic and environmental risk factors, disease outcome and responses to anti B-cell therapy belimumab indicate anti-CCP positive RA is a distinct disease entity. Arthritis and Rheumatism. 2006;54(Suppl. 9):
  34. Joske DJ, Ma DT, Langlands DR, et al. Autologous bone-marrow transplantation for rheumatoid arthritis. Lancet. 1997;350:337–338
  35. Verburg RJ, Sont JK, van Laar JM. Reduction of joint damage in severe rheumatoid arthritis by high-dose chemotherapy and autologous stem cell transplantation. Arthritis and Rheumatism. 2005;52:421–424
  36. Dwosh IL, Giles AR, Ford PM, et al. Plasmapheresis therapy in rheumatoid arthritis. A controlled, double-blind, crossover trial. The New England Journal of Medicine. 1983;308:1124–1129
  37. Sasso EH, Merrill C, Furst D. Is release of staphylococcal protein A during immunoabsorption therapy of rheumatoid arthritis related to clinical response?. Arthritis and Rheumatism. 2000;43(Suppl.):
  38. Felson DT, Lavalley MP, Baldassare AR, et al. The Prosorba column for treatment of refractory rheumatoid arthritis: a randomized, double-blind, sham-controlled trial. Arthritis and Rheumatism. 1999;42:2153–2159
  39. Iglesias J, D'Agati VD, Levine JS. Acute glomerulonephritis occurring during immunoadsorption with staphylococcal protein A column (Prosorba). Nephrology, Dialysis, Transplantation. 2004;19:3155–3159
  40. Poullin P, Announ N, Mugnier B, et al. Protein A-immunoadsorption (Prosorba column) in the treatment of rheumatoid arthritis. Joint, Bone, Spine. 2005;72:101–103
  41. Nawroth PP, Bank I, Handley D, et al. Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1. The Journal of Experimental Medicine. 1986;163:1363–1375
  42. Lam J, Takeshita S, Barker JE, et al. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. The Journal of Clinical Investigation. 2000;106:1481–1488
  43. Scott DL, Kingsley GH. Tumor necrosis factor inhibitors for rheumatoid arthritis. The New England Journal of Medicine. 2006;355:704–712
  44. van der Heijde DM. Overview of radiologic efficacy of new treatments. Rheumatic Diseases Clinics of North America. 2004;30:285–293vi
  45. Haraoui B, Cameron L, Ouellet M, et al. Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response. The Journal of Rheumatology. 2006;33:31–36
  46. Choy EH, Hazleman B, Smith M, et al. Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology (Oxford). 2002;41:1133–1137
  47. Arend WP, Dayer JM. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. Arthritis and Rheumatism. 1995;38:151–160
  48. Firestein GS, Boyle DL, Yu C, et al. Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis. Arthritis and Rheumatism. 1994;37:644–652
  49. Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. The New England Journal of Medicine. 2004;350:2167–2179
  50. Van Snick J. Interleukin-6: an overview. Annual Review of Immunology. 1990;8:253–278
  51. Maini RN, Taylor PC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis and Rheumatism. 2006;54:2817–2829
  52. Smolen JS, Aletaha D, Koeller M, et al. New therapies for treatment of rheumatoid arthritis. Lancet. 2007;
  53. Baslund B, Tvede N, Danneskiold-Samsoe B, et al. Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study. Arthritis and Rheumatism. 2005;52:2686–2692
  54. Weaver CT, Hatton RD, Mangan PR, et al. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annual Review of Immunology. 2007;25:821–852
  55. Asquith DL, McInnes IB. Emerging cytokine targets in rheumatoid arthritis. Current Opinion in Rheumatology. 2007;19:246–251
  56. Sweeney SE, Firestein GS. Mitogen activated protein kinase inhibitors: where are we now and where are we going?. Annals of the Rheumatic Diseases. 2006;65(Suppl. 3):iii83–iii88
  57. Kremer JM, Bloom BJ, Breedveld F, et al. A randomized, double-blind, placebo-controlled trial of 3 dose levels of CP-690, 550 versus placebo in the treatment of active rheumatoid arthritis. Arthritis and Rheumatism. 2006;54(Suppl. 9):
  58. Vanags D, Williams B, Johnson B, et al. Therapeutic efficacy and safety of chaperonin 10 in patients with rheumatoid arthritis: a double-blind randomised trial. Lancet. 2006;368:855–863

PII: S1521-6942(08)00009-0

doi: 10.1016/j.berh.2008.01.009

Best Practice & Research Clinical Rheumatology
Volume 22, Issue 2 , Pages 299-310 , April 2008

Article Tools

* Image Usage & Resolution